arrow_back Back to App

Digital Drug Information: Easier Access and Choice of Format

This new law aims to simplify access to drug information by allowing manufacturers to provide it primarily digitally. Citizens will still be able to request paper leaflets, ensuring flexibility and choice in accessing important data about their medications.
Key points
Drug information will be primarily available digitally, potentially allowing quicker access to updated data.
Patients and healthcare providers can still request paper copies of information at no extra cost.
Authorities will develop rules to minimize negative impacts of digital changes on pharmacies and prescribers.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_1503
Sponsor: Rep. Harshbarger, Diana [R-TN-1]
Process start date: 2023-03-09
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Prescription Information Modernization Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_1503.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-03-09.

What are the main provisions?

Key points include:

  • Drug information will be primarily available digitally, potentially allowing quicker access to updated data.
  • Patients and healthcare providers can still request paper copies of information at no extra cost.
  • Authorities will develop rules to minimize negative impacts of digital changes on pharmacies and prescribers.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Harshbarger, Diana [R-TN-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

CATEGORIES

Health